Accéder au contenu
Merck
  • Optimization of a High-Throughput 384-Well Plate-Based Screening Platform with Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 15442 Biofilms.

Optimization of a High-Throughput 384-Well Plate-Based Screening Platform with Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 15442 Biofilms.

International journal of molecular sciences (2020-04-30)
Shella Gilbert-Girard, Kirsi Savijoki, Jari Yli-Kauhaluoma, Adyary Fallarero
RÉSUMÉ

In recent years, bacterial infections have become a main concern following the spread of antimicrobial resistance. In addition, bacterial biofilms are known for their high tolerance to antimicrobials and they are regarded as a main cause of recalcitrant infections in humans. Many efforts have been deployed in order to find new antibacterial therapeutic options and the high-throughput screening (HTS) of large libraries of compounds is one of the utilized strategies. However, HTS efforts for anti-biofilm discovery remain uncommon. Here, we miniaturized a 96-well plate (96WP) screening platform, into a 384-well plate (384WP) format, based on a sequential viability and biomass measurements for the assessment of anti-biofilm activity. During the assay optimization process, different parameters were evaluated while using Staphylococcus aureus and Pseudomonas aeruginosa as the bacterial models. We compared the performance of the optimized 384WP platform to our previously established 96WP-based platform by carrying out a pilot screening of 100 compounds, followed by the screening of a library of 2000 compounds to identify new repurposed anti-biofilm agents. Our results show that the optimized 384WP platform is well-suited for screening purposes, allowing for the rapid screening of a higher number of compounds in a run in a reliable manner.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Resazurin sodium salt, powder, BioReagent
Sigma-Aldrich
Crystal Violet Solution
Sigma-Aldrich
Auranofin, ≥98% (HPLC)
Sigma-Aldrich
Dehydroabietic acid, ≥90% (LC/MS-ELSD)
Econazole, European Pharmacopoeia (EP) Reference Standard